{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-086389","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2025-09-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.314169+00:00","generated_at":"2026-05-17T06:59:44.380066+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Relmada adds NDV-01 and sepranolone; NDV-01 Phase 2 shows 91% CR rate, Phase 3 planned 1H 2026","bullets":["Added two Phase 2 candidates: NDV-01 (NMIBC) and sepranolone (Prader-Willi Syndrome/compulsivity disorders).","NDV-01 six-month Phase 2 follow-up: 91% complete response rate at any time point.","Phase 3 registrational trial for NDV-01 targeted for 1H 2026; regulatory filings and manufacturing scale-up underway.","Sepranolone Phase 2 study in PWS planned for 1H 2026; proof-of-concept data in Tourette's support.","Appointed Dr. Raj S. Pruthi as CMO–Oncology and Dr. Yair Lotan as Chair of Clinical Advisory Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-086389","json":"https://secwatch.observer/filing/0001213900-25-086389.json","markdown":"https://secwatch.observer/filing/0001213900-25-086389.md","text":"https://secwatch.observer/filing/0001213900-25-086389.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025086389/0001213900-25-086389-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025086389/ea0256582-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:59:44.380066+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}